Hospital

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

Emergency medicine pharmacists discuss how they used a gamified, PowerPoint-based virtual escape room to improve disaster preparedness training, strengthen critical thinking, and highlight the essential role of pharmacists in emergency management.

The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.

The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.

The research further emphasizes the need for more attention on both chronic kidney disease (CKD) and mental health conditions.

New RSV vaccines for older adults enhance prevention efforts, yet awareness and uptake remain low. Pharmacists play a crucial role in improving vaccination rates.

FDA approves daratumumab and hyaluronidase for treating newly diagnosed light chain (AL) amyloidosis, enhancing survival rates and treatment efficacy.

Selumetinib gains FDA approval for adults with neurofibromatosis type 1, offering hope for those with inoperable plexiform neurofibromas.

An evaluation of the different dosing and administration regimens of high-dose nitroglycerin for sympathetic crashing acute pulmonary edema.

With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin deficiency (hATd).

Plozasiran gains FDA approval to significantly lower triglycerides in adults with familial chylomicronemia syndrome, enhancing heart health management.

Epcoritamab-bysp demonstrated impressive response rates and improved progression-free survival.

Pharmacy team members who participated in a gamified virtual escape room reported higher levels of readiness and confidence to respond to emergency-scenario disaster events.

Neladalkib offers durable responses and reduced side effects in TKI-pretreated patients.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

SHR-A1811 is a novel HER2-targeting ADC comprised of trastuzumab linked to a topoisomerase I inhibitor payload via a cleavable linker.

The CLEAR framework helps guide pharmacists during the process of assessing and delabeling β-lactam allergies to improve patient outcomes.

New research shows that an increased consumption of ultraprocessed foods significantly raises prediabetes risk in young adults, highlighting urgent dietary intervention needs.

New research reveals similar severe outcomes for adults hospitalized with hMPV and RSV, emphasizing the need for awareness of both infections.

Ziftomenib gains FDA approval as a targeted treatment for relapsed acute myeloid leukemia with NPM1 mutations, offering new hope for patients.

Nazia Somani Babul, PharmD, BCACP, often serves as a primary or coinvestigator and collaborates with pharmacists, students, and residents.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

Only Humans Can Ensure AI Is Ethical and Unbiased

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.